Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Metaraminol→

Metaraminol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
54-49-9
Molecular formula
C9H13NO2
Molecular weight
167.2 g/mol
Drug class
Sympathomimetic vasopressorpredominantly alpha-adrenergic receptor agonist
Mechanism of action
Produces peripheral vasoconstriction primarily through alpha-adrenergic receptor stimulation, increasing systemic vascular resistance and arterial blood pressure. It also has indirect sympathomimetic effects through noradrenaline release.
Indications / reported uses
  • Treatment of acute hypotension, particularly during anaesthesia or in hospital settings, using intravenous or intramuscular formulations according to local product authorisation and monitored clinical practice

Sources: UK product information — Metaraminol injection · NLM MeSH — Metaraminol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Metaraminol Environmental Risk Assessment (ERA) (the Metaraminol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.